Post-menopausal women and osteoporosis: Available choices for maintenance of skeletal health

Maturitas

Volumn 30, Issue 3, 1998, Pages 241-245

  Termine, John D ^a   Wong, Mayme ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Hormone replacement therapy; Osteoporosis; Post menopausal; Selective estrogen receptor modulators

Indexed keywords

ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; GESTAGEN; MEDROXYPROGESTERONE ACETATE; RALOXIFENE;

ARTICLE; BONE DENSITY; BONE MINERAL; BREAST CANCER; CANCER RISK; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; MENOPAUSE; NONHUMAN; OVARIECTOMY; POSTMENOPAUSE OSTEOPOROSIS; TRANSDERMAL DRUG ADMINISTRATION;

ANIMALS; DISEASE MODELS, ANIMAL; EPIDEMIOLOGIC STUDIES; ESTROGEN ANTAGONISTS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; RANDOMIZED CONTROLLED TRIALS; RATS;

EID: 0032538823     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5122(98)00092-9     Document Type: Article

References (42)

1. Greenspan S.L., Maitland L.A., Myers E.R., Krasnow M.B., Kido T.H. Femoral bone loss progresses with age: A longitudinal study in women over age 65. J Bone Miner Res. 9:1994;1959-1965.
2. Cummings S.R., Black D.M., Nevitt M.C.et al. Bone density at various sites for prediction of hip fractures. Lancet. 341:1993;72-75.
3. Riggs B.L. Overview of osteoporosis. West J Med. 154:1991;63-77.
4. Kannus P., Parkkari J., Sievanen H., Heinonen A., Vuori I., Jarvinen M. Epidemiology of hip fractures. Bone. 18:1996;57S-63S.
5. Melton L.J. Hip fractures: A worldwide problem today and tomorrow. Bone. 14:1993;S1-S8.
6. Dempster D.W., Lindsay R. Pathogenesis of osteoporosis. Lancet. 341:1993;797-801.
7. Melton L.J., Atkinson E.J., O'Fallon W.M., Wahner H.W., Riggs B.L. Long-term fracture prediction by bone mineral assessed at different skeletal sites. J Bone Miner Res. 8:1997;1227-1233.
8. Johnston C.C. Development of clinical practice guidelines for prevention and treatment of osteoporosis. Calcif Tissue Int. 59(suppl. 1):1997;S30-S33.
9. Kanis J.A., Melton L.J., Christiansen C., Johnston C.C., Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res. 9:1994;1137-1141.
10. Epstein S. Serum and urinary markers of bone remodeling: Assessment of bone turnover. Endocr Rev. 9:1988;437-449.
11. Dawson-Hughes B., Harris S.S., Krall E.A., Dallal G.E. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. New Engl J Med. 337:1997;670-676.
12. Chapuy M.C., Arlot M.E., Duboeuf F.et al. Vitamin D3 and calcium to prevent hip fractures in elderly women. New Engl J Med. 327:1992;1637-1642.
13. Lobo R.A. Benefits and risks of estrogen replacement therapy. Am J Obstet Gynecol. 173:1995;982-990.
14. Grady D., Rubin S.M., Petitti D.B.et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 117:1992;1016-1037.
15. Collaborative Group on Hormonal Factors in Breast Cancer Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet. 350:1997;1047-1059.
16. Lindsay R., Tohme J.F. Estrogen treatment of patients with established postmenopausal osteoporosis. Obstet Gynecol. 76:1990;290-295.
17. Lufkin E.G., Wahner H.W., O'Fallon W.M.et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med. 117:1992;1-9.
18. Kiel D.P., Felson D.T., Anderson J.J., Wilson P.W.F., Moskowitz M.A. Hip fracture and the use of estrogens in postmenopausal women. New Engl J Med. 317:1987;1169-1174.
19. Cauley J.A., Seeley D.G., Ensrud K.E., Ettinger B., Black D.M., Cummings S.R. Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research Group. Ann Intern Med. 122:1995;9-16.
20. Colditz G.A., Hankinson S.E., Hunter D.J.et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. New Engl J Med. 332:1995;1589-1593.
21. Grodstein F., Stampfer M.J., Colditz G.A.et al. Postmenopausal hormone therapy and mortality. New Engl J Med. 336:1997;1769-1775.
22. Beresford S.A.A., Weiss N.S., Voigt L.F., McKnight B. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet. 349:1997;458-461.
23. Kauffman R.F., Bryant H.U. Selective estrogen receptor modulators. Drug News Perspect. 8:1995;531-539.
24. Baker V.L., Jaffe R.V. Clinical uses of antiestrogens. Obstet Gynecol Survey. 51:1995;45-59.
25. Beato M., Sanchez-Pacheco A. Interaction of steroid hormone receptors with the transcription initiation complex. Endocr Rev. 17:1996;587-609.
26. Yang N.N., Bryant H.U., Hardikar S.et al. Estrogen and raloxifene stimulate transforming growth factor-b3 gene expression in rat bone: A potential mechanism for estrogen- or raloxifene-mediated bone maintenance. Endocrinology. 137:1996;2075-2084.
27. Yang N.N., Venugopalan M., Hardikar S., Glasebrook A.L. Identification of an estrogen response element activated by metabolites of 17β-estradiol and raloxifene. Science. 273:1997;1222-1225.
28. Mitlak B.H., Cohen F.J. In search of optimal long-term female hormone replacement: The potential of selective estrogen receptor modulators. Horm Res. 48:1997;155-163.
29. Black L.J., Sato M., Rowley E.R.et al. Raloxifene (LY139481 HCl) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest. 93:1994;63-69.
30. Frolik C.A., Bryant H.U., Black E.C., Magee D.E., Chandrasekhar S. Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: Effects of raloxifene HCl, tamoxifen, estrogen and alendronate. Bone. 18:1996;621-627.
31. Sato M., Rippy M.K., Bryant H.U. Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats. FASEB J. 10:1996;905-912.
32. Evans G.L., Bryant H.U., Magee D.E., Sato M., Turner R.T. The effects of raloxifene on tibia histomorphometry in ovariectomized rats. Endocrinology. 134:1994;2283-2288.
33. Evans G.L., Bryant H.U., Magee D.E., Turner R.T. Raloxifene inhibits bone turnover and prevents further cancellous bone loss in adult ovariectomized rats with established osteopenia. Endocrinology. 137:1996;4139-4144.
34. Watts N.B., Harris S.T., Genant H.K.et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. New Engl J Med. 323:1990;73-79.
35. Draper M.W., Flowers D.E., Huster W.J., Neild J.A., Harper K.D., Arnaud C. A controlled trial of raloxifene (LY139481) HCl: Impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res. 11:1996;835-842.
36. Heaney R.P., Draper M.W. Raloxifene and estrogen: Comparative bone remodeling kinetics. J Clin Endocrinol Metab. 82:1997;3425-3429.
37. Delmas P.D., Bjarnason N.H., Mitlak B.H.et al. The effects of raloxifene on bone mineral density, serum cholesterol, and uterine endometrium in postmenopausal women. New Engl J Med. 337:1997;1641-1647.
38. Huster W, Shah A, Cohen FJ, Mitlak BH, Draper MW. Effect of raloxifene on the endometrium in healthy postmenopausal women. in: North American Menopause Society 8th Annual Meeting Program; 1997, Sep. 4-6; Boston. p. 54. Abstract nr. 54.
39. Scheele WH, Symanowski SM, Neale S, Lafortune M, Fugere P. A high dose of raloxifene HCl is not stimulatory in the uterus of healthy postmenopausal women. In: XV FIGO World Congress of Gynecology and Obstetrics Annual Meeting Program; 1997, Aug. 3-8; Copenhagen. Vojens: P.J. Schmidt A/S. p. 20. Abstract nr. FC702.5.
40. Scheele WH, Symanowski SM, Neale S, Shah A, Lafortune M, Fugere P. Raloxifene does not cause stimulatory effects on the uterus in healthy postmenopausal women (abstract). In: The Endocrine Society 79th Annual Meeting Program; 1997, Jun 11-14; Minneapolis. Bethesda (MD): The Endocrine Society Press. p. 498. Abstract nr. P3-246.
41. Boss S.M., Huster W.J., Neild J.A., Glant M.D., Eisenhut C.C., Draper M.W. Effects of raloxifene hydrochloride on the endometrium of postmenopausal women. Am J Obstet Gynecol. 177:1997;1458-1464.
42. Glusman JE, Lu Y, Huster WJ, Eckert S, Davies G, Lakshmanan M. Raloxifene effects on climacteric symptoms compared with hormone or estrogen replacement therapy (HRT or ERT). In: North American Menopause Society 8th Annual Meeting Program; 1997, Sep. 4-6; Boston. p. 65. Abstract nr. 97.040 P26.